APUS (Apimeds Pharmaceuticals, Inc.) Net earnings per share (EPS TTM)

Apimeds Pharmaceuticals (APUS) brings together experts in autoimmune pathologies, providing scientists with academic freedom. The business's venture success relies on FDA approval of bee venom-based drugs. The company creates natural alternatives to hormones for arthritis therapy. Analyzing this chart of the net income per share YoY ttm growth rate from GURU.Markets, it is evident that the parameter has stabilized at -1060.70.
APUS (Apimeds): analytical breakdowns and indicator data

EPS TTM dynamics measure the percentage change in earnings per share over the last twelve months, allowing for an assessment of fundamental growth momentum and capitalization efficiency. Analyzing the current YoY TTM growth in net income per share helps determine the extent to which the implementation of laboratory robotics and molecule screening automation at Apimeds Pharmaceuticals (APUS) is translating into actual financial results.